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As our scientific knowledge of bacteria grows, so does our ability to manipulate these bac-
teria to protect rather than infect mammalian hosts from a diverse group of diseases. The
old axiom that the best way to protect from a disease is to get infected in the first place is
not feasible in the face of the diverse group of pathogens that infect humans. Therefore, re-
programming bacteria to protect against diverse bacterial, viral, and parasitic diseases as
well as cancer is a new reality in the field of vaccines.
introduction
Vaccines remain the most effective tool
to prevent infectious diseases and also have
been evaluated as a therapeutic tool to treat
diseases such as cancer. A hallmark of a
good vaccine is the ability to induce long-
term protective immunity against a particu-
lar  pathogen.  The  immune  system  is
capable  of  recalling  encounters  with
pathogens and can still mount a protective
response decades after the initial contact [1].
This response to pathogens can be used ben-
eficially to design a vaccine vector capable
of eliciting the desired long-term immune
response. Bacterial vaccine vectors offer
multiple advantages: (1) there are several
well-characterized  virulence  attenuating
mutations; (2) the quantity and in vivo loca-
tion of antigen expression can be regulated;
(3) multiple vaccine delivery routes are pos-
sible; and (4) they are potent innate and
adaptive immune system stimulators. These
bacterial vaccine vectors can be used to im-
part protection against self-antigens as well
as heterologous antigens. For example, at-
tenuated Salmonella Typhimurium vaccine
vectors have been used to generate protec-
tive immune responses in mice and in some
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influenza), bacterial (e.g., Listeria monocy-
togenes, Streptococcus pneumonia), and pro-
tozoal (Plasmodium falciparum) pathogens,
as well as cancer [2-8]. The versatility and
immunogenicity of this platform make it an
excellent vaccine vector.
ViruLEncE AttEnuAtEd 
BActEriAL VEctorS
Historically,  virulence  attenuation  of
bacterial vaccine vectors was derived by
chemical mutagenesis and repeated labora-
tory passaging of virulent bacterial isolates.
Two modern examples of licensed live at-
tenuated bacterial vaccines derived in this
manner  are  Salmonella  enterica serovar
Typhi  Ty21a  and  Mycobacterium  bovis
BCG [9,10]. Nowadays, attenuated vaccine
vectors are constructed using recombinant
DNA technology based on current under-
standing of bacterial virulence. Several vir-
ulence  attenuated  strains  of  pathogenic
bacteria have been evaluated as vaccine vec-
tors, including strains of Salmonella spp., L.
monocytogenes,  Vibrio  cholera,  Shigella
spp., Yersinia enterocolitica, Bacilius an-
thracis,  Mycobacterium  bovis BCG,  and
Bordetella pertussis [11,12].
Virulence attenuated mutants must bal-
ance decreased reactogenicity with maximal
immunogenicity. Therefore, several differ-
ent virulence mutations have been studied,
alone and in combination, to determine suit-
able virulence attenuated bacterial vectors
for diverse antigens. A well-characterized
class of virulence attenuating mutations is
gene deletions that affect virulence gene reg-
ulation. One example of this class of viru-
lence  attenuated  bacterial  vectors  are
Salmonella spp. strains that contain dele-
tions in the phoP and/or phoQ genes [13].
These genes are part of a global virulence
regulatory system in Salmonella and com-
prise a two-component regulatory system
for phosphate sensing. These mutants have
been demonstrated to be non-reactogenic
and immunogenic in the context of an oral
Salmonella Typhi vaccine tested in humans
[14]. Auxotrophs are another important class
of virulence attenuated bacterial vectors.
Auxotrophic  mutants,  which  require  a
metabolite not available in vertebrate tis-
sues, generally undergo limited replication
once delivered to the host and are cleared
from the host within days to weeks. Aux-
otrophs that contain a deletion in a gene or
genes that are part of the aromatic amino
acid (aro) biosynthetic pathway have been
demonstrated to be attenuated as well as im-
munogenic in several bacterial strains, in-
cluding Salmonella spp., Bordetella spp., S.
flexneri, L. monocytogenes, and Y. enteroco-
litica [15-19]. Both of these classes of viru-
lence attenuated mutants make promising
bacterial vaccine vector candidates.
Some concerns with using live attenu-
ated bacterial vectors are the possibility of
pathogenic reversion of the vector once ad-
ministered and pre-existing immunity to the
vector.  One  way  to  circumvent  potential
pathogenic reversion is to introduce multi-
ple virulence attenuating mutations into the
bacterial vector. In addition, these mutations
should be capable of attenuation independ-
ently. Therefore, the risk of pathogenic re-
version as a result of recombination events
or horizontal gene transfer is virtually elim-
inated. Another risk with using pathogenic
bacteria as vaccine vectors is complications
that can arise due to pre-existing immunity.
Prior exposure to the bacterial vector has
been demonstrated to decrease efficacy of
the vaccine [20]. Thus, different bacterial
species or serotypes can be prepared as vac-
cine vectors depending on the prior expo-
sures of the population to be vaccinated as
well as whether the vaccine must be admin-
istered in multiple doses. By taking these
limitations into account during the initial
vaccine development, an effective virulence
attenuated bacterial vector can be designed
to virtually any disease.
AntiGEn EXPrESSion in 
BActEriAL VEctorS
Heterologous antigens can be expressed
either from chromosomally integrated anti-
gen cassettes or plasmid-based antigen ex-
pression systems in bacterial vaccine vectors.
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several advantages, including genetic stabil-
ity and the ability to integrate and express
multiple antigen genes. One substantial dis-
advantage of chromosomal integration is that
generally one copy of the antigen gene will
be expressed per bacterial cell; therefore, suf-
ficient  levels  of  the  antigen  may  not  be
reached to confer protection. One way to cir-
cumvent this limitation is to express the anti-
gen  from  a  plasmid.  The  quantity  and
location of antigen expression can be regu-
lated by using a plasmid-based system. The
amount of antigen expressed can be con-
trolled by using either high-copy or low-copy
plasmid backbones as well as inducible sys-
tems that produce large quantities of antigen
upon addition of the induction agent, such as
arabinose [21,22]. Furthermore, the location
of antigen expression can be controlled in
vivo to give the maximal antigen dosage de-
pending on subcellular localization. Constant
antigen synthesis can result in decreased bac-
terial vector fitness and decreased immuno-
genicity; therefore, using in vivo inducible
promoters to control antigen expression in a
plasmid can improve immune responses to
the bacterial vaccine vector. One example of
in vivo inducible promoters is the promoter
for the SalmonellaTyphimurium gene pagC,
which has been shown to have high in vivo
expression, while in vitro it is poorly ex-
pressed [23]. The model antigen OVA, when
expressed  from  the  pagC promoter,  was
shown to elicit potent cellular immune re-
sponses, compared to a promoter that was
not induced in vivo. Other promoters have
been studied that are induced in anaerobic
conditions or low-iron conditions [24,25].
Both of these conditions are found in host tis-
sues, and antigens expressed from these pro-
moters have had variable success in inducing
protective immune responses.
Concerns about plasmid stability are a
challenge with using a plasmid-based ex-
pression system in a bacterial vaccine vec-
tor.  Although  maintenance  of  plasmids
traditionally has been achieved though using
antibiotic  resistance  markers  in  bacteria,
safety concerns preclude the use of antibi-
otic selection with vaccine vectors. There-
fore,  antibiotic-free  plasmid  selection
methodologies have been developed for the
use in vaccine vectors [26]. In Salmonella, a
balanced-lethal plasmid system has been de-
veloped that is based on a gene, asd, re-
quired for the synthesis of diaminopimelic
acid (DAP†), an essential component of the
bacterial cell wall [27]. In Salmonella vec-
tors in which asd has been deleted from the
chromosome, complementation with a plas-
mid carrying an intact asd gene, as well as
the vaccine antigen, allows for the survival
of the bacteria in DAP-free environments
such as host tissues. This balanced-lethal ex-
pression system allows for the stable ex-
pression of vaccine antigens from a plasmid
in a bacterial vaccine vector.
dELiVErY oF LiVE-AttEnuAtEd
VAccinE VEctorS
Most pathogens are restricted by mu-
cosal membranes and have evolved elegant
mechanisms to either transit the mucosal bar-
rier or infect the cells that form the mucosal
membranes. Therefore,  vaccines  that  can
elicit a protective immune response directly
at the mucosal barrier are important to pro-
tect the host from subsequent infection. Sev-
eral  different  vaccine  vectors  have  been
developed to deliver antigens mucosally, in-
cluding viral particles, live-attenuated viral
vectors, liposomes, microspheres, ISCOMs,
transgenic plants, mucosal adjuvants, and
live-attenuated bacterial vectors [11,28]. Of
all these options, the live-attenuated bacter-
ial vectors are perhaps the best characterized.
These vectors can be delivered mucosally via
the oral, intranasal, rectal, vaginal, or inhala-
tion route and have been shown to not only
stimulate the mucosal immune response but
also a systemic immune response [29]. 
Bacterial vaccine vectors can overcome
the obstacles faced by antigens alone at mu-
cosal surfaces. These obstacles include en-
zymatic  degradation,  low  pH,  and  poor
absorption by mucosal cells. Since enteric
pathogens such as Salmonella spp., Shigella
spp., and Yersinia enterocolitica can serve
as bacterial vectors, the methods that these
bacteria use to infect the intestinal tract can
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cosal immune cells in the intestinal tract. For
example, Salmonella has been shown to tar-
get M cells during intestinal infection that
overlay the gut-associated lymphoid tissue
(GALT) [30]. The GALT is an inductive site
for immune responses and a key player in
the stimulation of mucosal immunity. Addi-
tionally, Salmonella is known to transverse
the enterocytes of the intestinal tract and ac-
cess the reticuloendothelial system which
can lead to systemic immune responses as
well [31]. Therefore, live bacterial vectors
make excellent vehicles for the delivery of
antigens at mucosal surfaces.
BActEriAL VEctorS AS PotEnt
iMMunE SYStEM StiMuLAtorS
The innate immune system can recog-
nize  microbes  directly  through  pattern
recognition receptors (PRRs) expressed on
innate immune cells such as dendritic cells
(DCs),  macrophages,  neutrophils,  mast
cells, endothelial cells, and fibroblasts. Al-
though it has been empirically shown that
the stimulation of the innate immune re-
sponse is key to mounting a protective adap-
tive immune response, only recently have
the mechanisms begun to be elucidated [32].
Bacterial vaccine vectors express many dif-
ferent molecular patterns that can be de-
tected by innate immune cells like DCs and
translated to the adaptive immune system
cells to modulate the type of immune re-
sponse (Th1 or Th2 biased), strength, and
persistence. 
The type of bacterial vector used as a
vaccine delivery vector plays a key role in
the  kind  of  adaptive  immune  response
elicited. The intracellular lifestyle of the bac-
terial vector (cytoplasmic versus membrane-
bound)  determines  whether  antigens  are
delivered to the MHC class I or class II path-
way. For some diseases, including those due
to viral and bacterial pathogens as well as
cancer, the mounting of a protective immune
response requires the delivery of antigens to
the MHC class I pathway so that protective
cytotoxic CD8+T cells are generated [33,34].
Both L. monocytogenes and Shigella spp.
vectors directly access the cytoplasmic com-
partment during intracellular infection and
can deliver antigens directly to the MHC
class I pathway while other bacterial vectors
such as Salmonellaspp. or M. bovisBCG re-
main localized in a membrane-bound com-
partment and inefficiently deliver antigens to
the MHC class I pathway [35,36]. In the case
of Salmonella spp., this deficiency can be
overcome by secretion of antigens through
the type III secretion system (T3SS) [3]. The
T3SS is basically a bacterial nanosyringe that
can be used to deliver proteins directly into
the cytosol of both antigen presenting cells
and non-phagocytic cells. By fusing the se-
cretion signal and chaperone binding domain
of a T3SS secreted effector protein to an anti-
genic peptide, virtually any antigen can be
delivered to the MHC class I pathway by
Salmonella [37]. The delivery of antigens
through the T3SS in Salmonella has been
shown to elicit protective cytotoxic CD8+ T
cells in mice to various viral, bacterial, and
parasitic diseases as well as cancer [38,39].
concLuSion
The use of live-attenuated bacterial vac-
cine vectors offers the potential of an orally
delivered vaccine that is capable of eliciting
protective mucosal and systemic immune re-
sponses. A range of heterologous antigens ex-
pressed in these vectors have been shown to
confer protection against disease in mice and
humans in some cases [40,41]. While much
research is being done in the field of live-at-
tenuated bacterial vaccine vectors, currently
there are no licensed vaccines that utilize this
approach, although several formations are in
clinical trials. Furthermore, as research con-
tinues to elucidate the key components that
are part of the balance between reactogenic-
ity and immunogenicity, even better vectors
can be developed. 
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